New technologies have revolutionized the antibody field by allowing the creation of libraries containing antibody fragments as scFv, Fab or nanobodies. Yet, the use of antibodies or fragments as therapeutics requires optimizing several of their key parameters as binding affinity, pharmacokinetics or folding stability. Addressing these challenges requires the use of a suitable computational platform.

Scaligner provides features to help scientists on the road to antibody therapeutics, and we are committed to continue its development to fulfill your needs.